ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Dec 03, 2021 15:00 JST
Source:
Acumen Diagnostics
Acumen Diagnostics' PCR capabilities to tackle Omicron COVID-19 variant
- Highly accurate, cost-effective, affordable PCR tests with 2 laboratories able to undertake 7000 tests daily
- PCR test kits able to detect COVID-19 positive cases including those infected with Omicron variant
- Homegrown medical technology company that is fully integrated to manufacture PCR test kits locally
- One of the few companies in Singapore with proprietary technology in testing
SINGAPORE, Dec 03, 2021 - (ACN Newswire) - Homegrown medical technology Company, Acumen Diagnostics Pte. Ltd. ("Acumen Diagnostics" or the "Company"), a 51% owned subsidiary of Q&M Dental Group (Singapore) and 49% owned by Aoxin Q&M Dental, today announced that its proprietary, locally-manufactured polymerase chain reaction ("PCR") test kits Acu-Corona 2.0 and Acu-Corona Duplex are able to detect COVID-19 positive cases infected with the Omicron variant.
Acumen Diagnostics' series of Acu-Corona and SatuGen COVID-19 PCR test kits can detect the presence of the Omicron variant in SARS-CoV-2 samples
Dr Ong Siew Hwa, Executive Director of Aoxin Q&M Dental and Chief Executive Officer & Chief Scientist of Acumen Diagnostics said, "As the COVID-19 threat continues to evolve with the emergence of a potentially more transmissible variant, Omicron, highly-accurate and cost-effective COVID-19 testing becomes even more important to detect and help curb the spread of the virus.
With PCR tests remaining the gold standard to detect COVID-19, Acumen Diagnostics remains well-positioned to help Singapore tackle this new challenge posed by the virus, with our effective and affordable PCR test kits that are equipped to detect COVID-19 positive cases infected with Delta and Omicron, as well as our laboratory testing capabilities that can run 7000 tests daily. We will continue to contribute to national COVID-19 testing efforts to support Singapore's safe and sustainable re-opening."
In addition to detecting COVID-19 positive cases infected with the Delta variant, the Company's proprietary PCR test kits are able to detect COVID-19 positive cases infected with the Omicron variant as well.
The Acu-Corona 2.0 PCR test targets two COVID-19 genes - RdRp and E, while the Acu-Corona Duplex PCR test targets the E gene and S gene. The portion of the S gene targeted by the Acu-Corona Duplex PCR test does not contain any of the 32 mutations that occurred in the Omicron variant, hence it can detect the Omicron variant without any loss of sensitivity.
This proprietary technology used in PCR test kits and laboratory testing is developed and owned by Acumen Diagnostics. Being locally manufactured, the Company's test kits can be deployed quickly and are more cost-effective and allow for greater self-sufficiency, compared to that of its peers imported from overseas.
Acumen Diagnostics possesses deep technical capabilities and the supporting infrastructure in molecular diagnostics, spanning R&D, manufacturing, and clinical laboratory testing, with 2 laboratories that are able to process 7000 COVID-19 diagnostics tests daily.
About Acumen Diagnostics Pte. Ltd.
Acumen Diagnostics Pte. Ltd. ("Acumen Diagnostics") is a homegrown Singaporean, award-winning medical technology company. It is fully integrated with functions in research and development, manufacturing, as well as commercialisation of molecular diagnostics by distribution as well as conducting clinical laboratory testing services for (including but not limited to) infectious diseases, cancer, and COVID-19. It has also actively established frontline services such as COVID-19 on-site swabbing operations.
Acumen Diagnostics is a 51% subsidiary of SGX-listed Q&M Dental Group (Singapore) Limited (SGX: 1D4.SI) and 49%-owned by SGX-listed Aoxin Q&M Dental Group Limited (SGX: QC7.SI). For more information, please visit the company website at www.acumen-research.com.
For more information, please contact:
Waterbrooks Consultants Pte. Ltd.
+65 6958 8008,
query@waterbrooks.com.sg
Wayne Koo (M): +65 9338 8166,
wayne.koo@waterbrooks.com.sg
Derek Yeo (M): +65 9791 4707,
derek@waterbrooks.com.sg
Source: Acumen Diagnostics
Sectors: Daily Finance, BioTech, Healthcare & Pharm, Local Biz, Government
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
TOYOTA GAZOO Racing back in Brazil
Jul 05, 2024 17:55 JST
World's first observation of magnetic fields of individual lattice planes achieved using Hitachi's atomic-resolution holography electron microscope
Jul 04, 2024 18:31 JST
World's first* supply chain established for more sustainable polyester fiber based on CO2-derived material as well as renewable and bio-based materials
Jul 04, 2024 17:33 JST
MHI Receives Order for Ultrasonic Thickness Monitoring System That Can Be Used in Environments with Flammable Gas
Jul 04, 2024 13:59 JST
Fujitsu and ANU to bring world-class quantum computing to Australia
Jul 04, 2024 08:49 JST
TANAKA Precious Metals to Provide Award Items and Ceremony Souvenirs for the International Friendly Matches of the Japan Men's National Blind Football Team at the "DAICEL Blind Football Japan Cup 2024 in Osaka" to Begin on July 4
Jul 04, 2024 03:00 JST
MHI Thermal Systems Launches New Remote Control Unit for Commercial Air-Conditioners in Europe
Jul 03, 2024 14:20 JST
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC)
Jul 02, 2024 13:01 JST
JCB and Taishin Bank Launch New JCB Apollo Card rewarding Taishin points in Taiwan and Japan
Jul 02, 2024 12:00 JST
NTT DOCOMO GLOBAL Commences Business Operations
Jul 02, 2024 09:30 JST
NEC awarded by e& for contributions to digital transformation and partnership strength
Jul 01, 2024 23:00 JST
Supersub Rovanpera claims remarkable win for TOYOTA GAZOO Racing
Jul 01, 2024 11:14 JST
Mazda: Announcement by Ministry of Land, Infrastructure, Transport and Tourism Regarding Applications for Type Designation
Jul 01, 2024 10:53 JST
Singtel and Hitachi Digital Partner to Accelerate Industrial AI Solutions
Jul 01, 2024 10:37 JST
Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China
Jun 28, 2024 15:57 JST
Amogy and Mitsubishi Shipbuilding Have Completed a Feasibility Study of Ammonia Supply System for Ammonia-Powered Maritime Solution
Jun 28, 2024 12:40 JST
MHI Invests in e-Zinc to Advance Long-duration Energy Storage in Zinc Metal
Jun 28, 2024 11:30 JST
DENSO Announces Personnel Changes
Jun 28, 2024 11:09 JST
Boosting Growth Investment to Power Mobility Company Transformation Toyota-AISIN Capital Ties Revised
Jun 27, 2024 16:23 JST
Mazda Production and Sales Results for May 2024
Jun 27, 2024 16:02 JST
More Latest Release >>
Related Release
Acumen Diagnostics granted Ministry of Health COVID-19 offsite PCR testing license, up to 100 sites island-wide
December 16 2021 11:00 JST
More Press release >>